🔗 Share this article

Given that the US continues making historic changes to its vaccine guidelines, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by casting doubt on Covid vaccines throughout the pandemic and has focused upon alleged fatalities after COVID-19 immunization in her recent tenure at the FDA.

Scheduled Shifts to Pediatric Vaccine Program

Public health authorities planned to announce sweeping revisions to the childhood immunization program recently, bringing the US with Denmark’s national calendar, it is understood – a major change that would put the US at odds with much of the international standard with insufficient data for public health gain. The planned update has been delayed until the new year.

In place of the top vaccines chief, Dr. Høeg is listed to address the audience at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to run the division this calendar year.

A New Direction at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics branches as Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending certain pediatric immunization guidelines in the US in order to be more in line with the Danish model, a society with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – typically the purview of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no apparent track record in pharmaceutical research, oversight or leadership, which has been standard for past directors of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for leading the CDER, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She lacks background in drug approvals.”

Past commissioners of the center would “be deeply familiar with laws and regulations and the research of drug development”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that previous people who led the center have had.”

This division has an enormous portfolio at the FDA, she emphasized.

“Many people just pays attention on the novel medication approvals, but the generic program authorizes thousands of generic medications. There is also a biosimilars division, over-the-counter program and more, and each of these have to be managed,” she noted. “The thing you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a significant leadership component to the role, which manages in excess of 5,000 staff members. “It is a huge management job, if you do it right,” the former official concluded.

Response and Disputed Programs

In response to concerns about Høeg’s fitness for the role and whether this selection indicates more teamwork among FDA leaders on vaccines, a press secretary said that the “concerns rely on flawed assumptions”.

“This background is consistent with the functions of her role,” the official said, pointing to the period Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's controversial priority voucher program, a controversial rapid medication authorization process that apparently worried her former heads. “By what process are these medications being selected for this fast-track system? Who takes the decisions?” Howard said. “There is a lot of lack of transparency happening at the regulatory body right now.”

In general, he said, “the FDA looks to be trending towards laxer regulations of pharmaceuticals, aside from shots.”

Documented Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if concerning, past, some experts observe. She published a analysis using unverified public submissions to estimate the incidence of myocarditis following COVID-19 immunization. She counseled the Florida top health official Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Part of her “policy goals” for the current federal leadership encompassed changing rules for recently developed shots and ending “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has reportedly suggested excluding adolescent males from receiving COVID-19 vaccines.

“She’s an all-around ideologue who commences with her beliefs and works backwards to retrofit the evidence in a highly disingenuous, untruthful way,” Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|